267 related articles for article (PubMed ID: 21549568)
1. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
Krakowski M; Czobor P
Schizophr Res; 2011 Aug; 130(1-3):27-33. PubMed ID: 21549568
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Krakowski MI; Czobor P; Nolan KA
J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
[TBL] [Abstract][Full Text] [Related]
3. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
5. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
[TBL] [Abstract][Full Text] [Related]
8. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
11. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
[TBL] [Abstract][Full Text] [Related]
13. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Smith RC; Infante M; Singh A; Khandat A
Int J Neuropsychopharmacol; 2001 Sep; 4(3):239-50. PubMed ID: 11669086
[TBL] [Abstract][Full Text] [Related]
14. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
15. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Lieberman JA
J Clin Psychopharmacol; 2004 Apr; 24(2):225-8. PubMed ID: 15206671
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
[No Abstract] [Full Text] [Related]
18. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics.
Potkin SG; Fleming K; Jin Y; Gulasekaram B
J Clin Psychopharmacol; 2001 Oct; 21(5):479-83. PubMed ID: 11593072
[TBL] [Abstract][Full Text] [Related]
19. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.
Kumra S; Kranzler H; Gerbino-Rosen G; Kester HM; DeThomas C; Cullen K; Regan J; Kane JM
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):307-16. PubMed ID: 18759640
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Bitter I; Czobor P; Dossenbach M; Volavka J
Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]